Chemotherapy drug temozolomide analog shows promise in treating glioma

Credit: Unsplash/CC0 Public Domain

A team of researchers from Yale University and Yale School of Medicine has developed a temozolomide analog for use as a chemotherapy drug in treating glioma. In their paper published in the journal Science, the researchers describe the new drug and how it works to kill brain tumor cells. Roger Reddel and Adel Aref, with the University of Sydney's Children's Medical Research Institute, have published a Perspective piece in the same journal issue outlining the work done by the team in New Jersey

As the researchers note, glioblastoma (GBM) is the most common type of brain tumor in humans—it is also the most deadly. Just 5% of patients live five years beyond diagnosis. Treatment for patients with GBM involves and prescription of the chemotherapy drug temozolomide (TMZ). Such is generally geared to prolonging life, not saving it. In this new effort, the researchers have developed a TMZ analog that has thus far proven to be more effective at killing GBM than standard TMZ.

TMZ works, Reddel and Aref, explain, by taking advantage of a GBM weakness—its cells are deficient in O6-methylguanine methyl transferase, (MGMT)—a protein that repairs DNA. Treatment with TMZ results in the development of DNA lesions that lead to cells self-destructing—the cancer cells die while the healthy brain cells survive by healing themselves. Unfortunately, patients tend to develop a resistance to the drug, which reduces its effectiveness until it is no longer useful. In this new effort, the researchers created a TMZ-like drug that also leads to DNA lesions and cells self-destructing but they made a change that prevents the from developing a resistance to it.

The change by the researchers involved adding an interstrand crosslinking agent, which, as its name implies, involves creating links between strands of DNA—but it does it in a way that allows healthy cells to reverse the process. In , on the other hand, the link is too strong for the GBM cells to overcome, so they wind up self-destructing—at least in mice models. The end result, the researchers believe, is a TMZ analog that will not allow mutations to pop up in the MMR pathway, which means the GBM cells should have no way to develop resistance.

Explore further

New drug that can prevent drug resistance and adverse effects

More information: Kingson Lin et al, Mechanism-based design of agents that selectively target drug-resistant glioma, Science (2022). DOI: 10.1126/science.abn7570

Roger Reddel et al, Targeting brain cancer, Science (2022). DOI: 10.1126/science.add4839

Journal information: Science

© 2022 Science X Network

Citation: Chemotherapy drug temozolomide analog shows promise in treating glioma (2022, July 29) retrieved 18 August 2022 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors